You are not logged in.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy

Broadley,SA, Barnett,MH, Boggild,M, Brew,BJ, Butzkueven,H, Heard,R, Hodgkinson,S, Kermode,AG, Lechner-Scott,J, Macdonell,RA, Marriott,M, Mason,DF, Parratt,J, Reddel,SW, Shaw,CP, Slee,M, Spies,J, Taylor,BV, Carroll,WM, Kilpatrick,TJ, King,J, McCombe,PA, Pollard,JD and Willoughby,E 2014, Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy, Journal of clinical neuroscience, vol. 21, no. 11, pp. 1847-1856, doi: 10.1016/j.jocn.2014.01.018.

Attached Files
Name Description MIMEType Size Downloads

Title Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy
Author(s) Broadley,SA
Barnett,MH
Boggild,M
Brew,BJ
Butzkueven,H
Heard,R
Hodgkinson,S
Kermode,AG
Lechner-Scott,J
Macdonell,RA
Marriott,M
Mason,DF
Parratt,J
Reddel,SW
Shaw,CP
Slee,M
Spies,J
Taylor,BV
Carroll,WM
Kilpatrick,TJ
King,J
McCombe,PA
Pollard,JD
Willoughby,E
Journal name Journal of clinical neuroscience
Volume number 21
Issue number 11
Start page 1847
End page 1856
Publisher Elsevier
Place of publication London, England
Publication date 2014-11
ISSN 1532-2653
Keyword(s) Evidence-based medicine
Guideline
Multiple sclerosis
Review
Treatment
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences
Neurosciences & Neurology
STEM-CELL TRANSPLANTATION
PLACEBO-CONTROLLED TRIAL
SECONDARY-PROGRESSIVE MS
RELAPSING-REMITTING MS
RANDOMIZED CONTROLLED TRIAL
INTERFERON BETA-1A THERAPY
CONTROLLED PHASE-3 TRIAL
FUMARIC-ACID ESTERS
5-YEAR FOLLOW-UP
OPEN-LABEL TRIAL
Summary In Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer and emerging therapies alongside the existing therapies. The effectiveness of β-interferon in the treatment of different stages and the different disease courses of MS is critically reviewed with the conclusion that the absolute level of response in term of annualised relapse rates (where relapses occur) and MRI activity are similar, but are disappointing in terms of sustained disability progression for progressive forms of the disease. Finally we review the controversial area of combination therapy for MS. Whilst it remains the case that we have no cure or means of preventing MS, we do have a range of effective therapies that when used appropriately and early in the disease course can have a significant impact on short term and longer term outcomes.
Language eng
DOI 10.1016/j.jocn.2014.01.018
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 929999 Health not elsewhere classified
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2014, Elsevier
Persistent URL http://hdl.handle.net/10536/DRO/DU:30070063

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 6 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 43 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Thu, 26 Feb 2015, 10:39:52 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.